Lyra Therapeutics (LYRA) Interest & Investment Income (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Interest & Investment Income of $1.1 million in Q4 2025, up 280.2% on a QoQ basis from $298000.0 in Q1 2025, and up 160.46% YoY from $435000.0 in Q4 2024.
Lyra Therapeutics (LYRA) Interest & Investment Income (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Interest & Investment Income for 7 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- Interest & Investment Income for Q4 2025 came in at $1.1 million, up 160.46% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.4 million (up 46.92% YoY), and the FY2025 annual result was $1.1 million, down 61.62% from the prior year.
- Interest & Investment Income for Q4 2025 stood at $1.1 million, up from $298000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.1 million in Q4 2025, with the low at -$3.1 million in Q4 2023.
- A 5-year average of $76000.0 and a median of $27500.0 in 2021 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 7557.14% in 2023, down 3102.04% in 2023.
- Lyra Therapeutics' Interest & Investment Income stood at $21000.0 in 2021, then tumbled by 566.67% to -$98000.0 in 2022, then slumped by 3102.04% to -$3.1 million in 2023, then jumped by 113.86% to $435000.0 in 2024, then surged by 160.46% to $1.1 million in 2025.
- The last three Interest & Investment Income figures came in at $1.1 million (Q4 2025), $298000.0 (Q1 2025), and $435000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 169,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 298,000.00 |
| Dec 31, 2024 | 435,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | -29,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | -3.14 Mn |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 897,000.00 |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | -98,000.00 |
| Sep 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 34,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 21,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 29,000.00 |
| Dec 31, 2020 | 32,000.00 |
| Sep 30, 2020 | 29,000.00 |